Patents by Inventor Loren A. Ornelas

Loren A. Ornelas has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11970714
    Abstract: Described herein are methods and compositions related to generation of induced pluripotent stem cells (iPSCs). Improved techniques for establishing highly efficient, reproducible reprogramming using non-integrating episomal plasmid vectors. Using the described reprogramming protocol, one is able to consistently reprogram non-T cells with close to 100% success from non-T cell or non-B cell sources. Further advantages include use of a defined reprogramming media E7 and using defined clinically compatible substrate recombinant human L-521. Generation of iPSCs from these blood cell sources allows for recapitulation of the entire genomic repertoire, preservation of genomic fidelity and enhanced genomic stability.
    Type: Grant
    Filed: July 2, 2020
    Date of Patent: April 30, 2024
    Assignee: Cedars-Sinai Medical Center
    Inventors: Dhruv Sareen, Loren A. Ornelas, Clive Svendsen
  • Publication number: 20230340420
    Abstract: Described herein are methods and compositions related to generation of induced pluripotent stem cells (iPSCs). Improved techniques for establishing highly efficient, reproducible reprogramming using non-integrating episomal plasmid vectors. Using the described reprogramming protocol, one is able to consistently reprogram non-T cells with close to 100% success from non-T cell or non-B cell sources. Further advantages include use of a defined reprogramming media E7 and using defined clinically compatible substrate recombinant human L-521. Generation of iPSCs from these blood cell sources allows for recapitulation of the entire genomic repertoire, preservation of genomic fidelity and enhanced genomic stability.
    Type: Application
    Filed: January 9, 2023
    Publication date: October 26, 2023
    Applicant: CEDARS-SINAI MEDICAL CENTER
    Inventors: Dhruv Sareen, Loren A. Ornelas, Clive Svendsen
  • Patent number: 11572545
    Abstract: Described herein are methods and compositions related to generation of induced pluripotent stem cells (iPSCs). Improved techniques for establishing highly efficient, reproducible reprogramming using non-integrating episomal plasmid vectors. Using the described reprogramming protocol, one is able to consistently reprogram non-T cells with close to 100% success from non-T cell or non-B cell sources. Further advantages include use of a defined reprogramming media E7 and using defined clinically compatible substrate recombinant human L-521. Generation of iPSCs from these blood cell sources allows for recapitulation of the entire genomic repertoire, preservation of genomic fidelity and enhanced genomic stability.
    Type: Grant
    Filed: June 16, 2017
    Date of Patent: February 7, 2023
    Assignee: Cedars-Sinai Medical Center
    Inventors: Dhruv Sareen, Loren A. Ornelas, Clive Svendsen
  • Publication number: 20200370023
    Abstract: Described herein are methods and compositions related to generation of induced pluripotent stem cells (iPSCs). Improved techniques for establishing highly efficient, reproducible reprogramming using non-integrating episomal plasmid vectors. Using the described reprogramming protocol, one is able to consistently reprogram non-T cells with close to 100% success from non-T cell or non-B cell sources. Further advantages include use of a defined reprogramming media E7 and using defined clinically compatible substrate recombinant human L-521. Generation of iPSCs from these blood cell sources allows for recapitulation of the entire genomic repertoire, preservation of genomic fidelity and enhanced genomic stability.
    Type: Application
    Filed: July 2, 2020
    Publication date: November 26, 2020
    Applicant: CEDARS-SINAI MEDICAL CENTER
    Inventors: Dhruv Sareen, Loren A. Ornelas, Clive Svendsen
  • Publication number: 20200332316
    Abstract: Described herein are reprogramming techniques allowing for production of mammary-derived iPSCs (“m-iPSCs”). The m-iPSCs described herein exhibit all the hallmarks of stem cell identity including round cluster, bright colony morphology, clonal expansion, and pluripotent marker expression (alkaline phosphatase expression, Oct-4, nanog, etc.) Further refined techniques allow for generation of m-iPSCs under essentially defined conditions.
    Type: Application
    Filed: June 30, 2020
    Publication date: October 22, 2020
    Applicant: CEDARS-SINAI MEDICAL CENTER
    Inventors: Xiaojiang Cui, Dhruv Sareen, Loren A. Ornelas
  • Patent number: 10745671
    Abstract: Described herein are methods and compositions related to generation of induced pluripotent stem cells (iPSCs). Improved techniques for establishing highly efficient, reproducible reprogramming using non-integrating episomal plasmid vectors. Using the described reprogramming protocol, one is able to consistently reprogram non-T cells with close to 100% success from non-T cell or non-B cell sources. Further advantages include use of a defined reprogramming media E7 and using defined clinically compatible substrate recombinant human L-521. Generation of iPSCs from these blood cell sources allows for recapitulation of the entire genomic repertoire, preservation of genomic fidelity and enhanced genomic stability.
    Type: Grant
    Filed: January 14, 2019
    Date of Patent: August 18, 2020
    Inventors: Dhruv Sareen, Loren A. Ornelas, Clive Svendsen
  • Patent number: 10738323
    Abstract: Described herein are reprogramming techniques allowing for production of mammary-derived iPSCs (“m-iPSCs”). The m-iPSCs described herein exhibit all the hallmarks of stem cell identity including round cluster, bright colony morphology, clonal expansion, and pluripotent marker expression (alkaline phosphatase expression, Oct-4, nanog, etc.) Further refined techniques allow for generation of m-iPSCs under essentially defined conditions.
    Type: Grant
    Filed: July 11, 2014
    Date of Patent: August 11, 2020
    Assignee: Cedars-Sinai Medical Center
    Inventors: Xiaojiang Cui, Sareen Dhruv, Loren A. Ornelas
  • Publication number: 20190194624
    Abstract: Described herein are methods and compositions related to generation of induced pluripotent stem cells (iPSCs). Improved techniques for establishing highly efficient, reproducible reprogramming using non-integrating episomal plasmid vectors. Using the described reprogramming protocol, one is able to consistently reprogram non-T cells with close to 100% success from non-T cell or non-B cell sources. Further advantages include use of a defined reprogramming media E7 and using defined clinically compatible substrate recombinant human L-521. Generation of iPSCs from these blood cell sources allows for recapitulation of the entire genomic repertoire, preservation of genomic fidelity and enhanced genomic stability.
    Type: Application
    Filed: June 16, 2017
    Publication date: June 27, 2019
    Applicant: Cedars-Sinai Medical Center
    Inventors: Dhruv SAREEN, Loren A. ORNELAS, Clive SVENDSEN
  • Publication number: 20190136203
    Abstract: Described herein are methods and compositions related to generation of induced pluripotent stem cells (iPSCs). Improved techniques for establishing highly efficient, reproducible reprogramming using non-integrating episomal plasmid vectors. Using the described reprogramming protocol, one is able to consistently reprogram non-T cells with close to 100% success from non-T cell or non-B cell sources. Further advantages include use of a defined reprogramming media E7 and using defined clinically compatible substrate recombinant human L-521. Generation of iPSCs from these blood cell sources allows for recapitulation of the entire genomic repertoire, preservation of genomic fidelity and enhanced genomic stability.
    Type: Application
    Filed: January 14, 2019
    Publication date: May 9, 2019
    Applicant: CEDARS-SINAI MEDICAL CENTER
    Inventors: Dhruv Sareen, Loren A. Ornelas, Clive Svendsen
  • Patent number: 10221395
    Abstract: Described herein are methods and compositions related to generation of induced pluripotent stem cells (iPSCs). Improved techniques for establishing highly efficient, reproducible reprogramming using non-integrating episomal plasmid vectors. Using the described reprogramming protocol, one is able to consistently reprogram non-T cells with close to 100% success from non-T cell or non-B cell sources. Further advantages include use of a defined reprogramming media E7 and using defined clinically compatible substrate recombinant human L-521. Generation of iPSCs from these blood cell sources allows for recapitulation of the entire genomic repertoire, preservation of genomic fidelity and enhanced genomic stability.
    Type: Grant
    Filed: June 16, 2016
    Date of Patent: March 5, 2019
    Assignee: Cedars-Sinai Medical Center
    Inventors: Dhruv Sareen, Loren A. Ornelas, Clive Svendsen
  • Publication number: 20170362574
    Abstract: Described herein are methods and compositions related to generation of induced pluripotent stem cells (iPSCs). Improved techniques for establishing highly efficient, reproducible reprogramming using non-integrating episomal plasmid vectors. Using the described reprogramming protocol, one is able to consistently reprogram non-T cells with close to 100% success from non-T cell or non-B cell sources. Further advantages include use of a defined reprogramming media E7 and using defined clinically compatible substrate recombinant human L-521. Generation of iPSCs from these blood cell sources allows for recapitulation of the entire genomic repertoire, preservation of genomic fidelity and enhanced genomic stability.
    Type: Application
    Filed: June 16, 2016
    Publication date: December 21, 2017
    Applicant: Cedars-Sinai Medical Center
    Inventors: Dhruv Sareen, Loren A. Ornelas, Clive Svendsen
  • Publication number: 20170107498
    Abstract: Described herein are methods and compositions related to generation of induced pluripotent stem cells (iPSCs). Improved techniques for establishing highly efficient, reproducible reprogramming using non-integrating episomal plasmid vectors, including generation of iPSCs from lymphoblastoid B-cells and lymphoblastoid B-cell lines. Such methods and compositions find use in regenerative medicine applications.
    Type: Application
    Filed: June 5, 2015
    Publication date: April 20, 2017
    Applicant: Cedars-Sinai Medical Center
    Inventors: Dhruv Sareen, Loren Ornelas, Robert Barrett
  • Publication number: 20160145642
    Abstract: Described herein are reprogramming techniques allowing for production of mammary-derived iPSCs (“m-iPSCs”). The m-iPSCs described herein exhibit all the hallmarks of stem cell identity including round cluster, bright colony morphology, clonal expansion, and pluripotent marker expression (alkaline phosphatase expression, Oct-4, nanog, etc.) Further refined techniques allow for generation of m-iPSCs under essentially defined conditions.
    Type: Application
    Filed: July 11, 2014
    Publication date: May 26, 2016
    Applicant: Cedars-Sinai Medical Center
    Inventors: Xiaojiang Cui, Sareen Dhruv, Loren A. Ornelas